Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius USA complaint handling procedures are inadequate -- FDA warning letter.

This article was originally published in The Gray Sheet

Executive Summary

FRESENIUS USA HEMODIALYZER/REPROCESSOR UNANTICIPATED DEVICE FAILURES should have been categorized by the company as complaints and investigated pursuant to good manufacturing practices (GMP) requirements, FDA says in a May 25 warning letter to the Walnut Creek, California-based firm. Review of service repair records for 40 Model 2008E and 55 Model 2008H hemodialysis machines, manufactured between March 1993 and March 1994, "showed at least 30 unanticipated device failures which were not identified, reviewed or evaluated as complaints," FDA says. In addition, review of service repair records for five Fresenius DRS-4 dialyzer reprocessing systems "found at least 11 reports of unanticipated device failures" that were not treated as complaints.

You may also be interested in...



Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel